Clinical Research Directory

Inclusion Criteria: 1. Be 18 years or older. 2. Be male or non-pregnant females who agree to comply with applicable contraceptive requirements of the protocol. 3. Histologically and/or cytologically confirmed gastrointestinal tumours that are metastatic or unresectable, and are subject to receive FOLFOX ± Bevacizumab. (ARM VII): Patients must have received only 1 prior line of therapy in the metastatic setting. 4. Have measurable disease according to RECIST v1.1. 5. Have an anticipated survival of at least 16 weeks. 6. Be ambulatory, with an ECOG performance score of 0 or 1. 7. Have adequate organ function. 8. Be on stable doses of any drugs that may affect hepatic drug metabolism or renal drug excretion. 9. Be fully informed about their illness and the investigational nature of the study protocol, and sign a REB-approved Informed Consent Form (ICF). 10. (ARM VII): BRAF wild-type tumour status. Exclusion Criteria: 1. Neuropathy \> grade 2 2. Previous intolerance to or significant reaction secondary to fluorouracil, oxaliplatin, or bevacizumab. 3. Cerebrovascular accident within the past 6 months before the start of treatment. 4. History or presence of central nervous system (CNS) metastasis or leptomeningeal tumours. 5. Any serious medical conditions that might be aggravated by treatment or limit compliance. 6. Any history of serious cardiac illness. 7. Hemoptysis, cerebral, or clinically significant gastrointestinal hemorrhage in the past 6 months before the start of treatment. 8. Any other known malignancy within 3 years before the start of treatment. 9. Active gastrointestinal tract disease with malabsorption syndrome. 10. Non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease. 11. Treatment with radiation therapy or surgery within 4 weeks prior to starting treatment. 12. Recent history of weight loss \> 10% of current body weight in past 3 months before the start of treatment. 13. HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent. 14. Concurrent use of another investigational therapy or anti-cancer therapy within 4 weeks before the start of treatment. 15. Currently breastfeeding 16. Dihydropyrimidine Dehydrogenase (DPD) deficiency 17. Current or prior treatment with potent inhibitors of Dihydropyrimidine Dehydrogenase (DPD) 18. (ARM VII): Prior exposure to BOLD-100 19. (ARM VII): Subjects with microsatellite-high (MSI-H) Tumours 20. (ARM VII): Concurrent monoclonal antibody therapy for mCRC (anti-EGFR, anti-VEGF or anti-HER2)